Zynerba Pharmaceuticals, Inc. (ZYNE)
Market Cap | 20.30M |
Revenue (ttm) | n/a |
Net Income (ttm) | -35.04M |
Shares Out | 47.06M |
EPS (ttm) | -0.82 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 50,079 |
Open | 0.430 |
Previous Close | 0.440 |
Day's Range | 0.413 - 0.440 |
52-Week Range | 0.390 - 2.150 |
Beta | 1.74 |
Analysts | Buy |
Price Target | 5.55 (+1,221.11%) |
Earnings Date | May 15, 2023 |
About ZYNE
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is h... [Read more]
Full Company ProfileFinancial Performance
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for ZYNE stock is "Buy." The 12-month stock price forecast is $5.55, which is an increase of 1,221.11% from the latest price.
News

Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights
Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with Fragile X syndrome; topline results expected first-half 2024

Zynerba Pharmaceuticals Confirms Not Holding Cash Deposits or Securities at Silicon Valley Bank
DEVON, Pa., March 13, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychi...

Zynerba Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference
DEVON, Pa, March 07, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychia...

Zynerba Pharmaceuticals to Present at the Cowen 43rd Annual Health Care Conference
DEVON, Pa., March 01, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychi...

Zynerba Pharmaceuticals Announces Publication in the Journal of Neurodevelopmental Disorders Describing the Role of the Endocannabinoid System and Cannabidiol Therapy in Fragile X Syndrome
Comprehensive data review suggests a central role for the endocannabinoid system (ECS) in neuronal development, cognitive function and in the pathogenesis of Fragile X syndrome (FXS)

Rising P/E: An Overlooked Way to Pick 5 Winning Stocks
Want to try a different approach? Tap five stocks with increasing P/E ratios.

Zynerba Pharmaceuticals Announces Update on RECONNECT, the Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome
RECONNECT initial screening visits are being adversely impacted by environmental factors, such as the “Tripledemic” (high rates of RSV, influenza and COVID-19); topline results now expected first half...

Zynerba Pharmaceuticals Announces Positive Long-Term Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at the Annual Meeting of the American College of Neuropsychopharmacology
Zygel™ achieved statistically significant and clinically meaningful improvements from baseline in multiple efficacy assessments and was generally well-tolerated through 38 weeks of treatment

Zynerba Pharmaceuticals Announces Poster Presentation at the Annual Meeting of the American College of Neuropsychopharmacology
DEVON, Pa., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychia...

Zynerba Pharmaceuticals Announces Publication of Data from Phase 3 CONNECT-FX Study of Zygel™ in the Journal of Neurodevelopmental Disorders
Study finds patients with Fragile X who have a highly methylated FMR1 gene that were treated with Zygel showed a significant reduction in behavioral symptoms compared to those treated with placebo

Zynerba Pharmaceuticals Announces European Commission Has Granted Orphan Drug Designation for Zygel™ in 22q11.2 Deletion Syndrome
DEVON, Pa., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychia...

Zynerba Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Highlights
Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with Fragile X syndrome (FXS); topline results expected second-half 2023

Zynerba Pharmaceuticals Announces Issuance of New U.S. Patent for Zygel™ for the Treatment of 22q11.2 Deletion Syndrome
DEVON, Pa., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychia...

Zynerba Pharmaceuticals Announces Poster Presentation at the National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit
DEVON, Pa., Oct. 10, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychia...

Zynerba Pharmaceuticals Announces Issuance of New U.S. Patent for Zygel™
DEVON, Pa., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychia...

Zynerba Pharmaceuticals to Participate in the Cantor Neurology & Psychiatry Conference
DEVON, Pa., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychi...

Zynerba Pharmaceuticals to Present at the Ladenburg Thalmann Healthcare Conference
DEVON, Pa., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychi...

Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q at The Society for the Study of Behavioural Phenotypes (SSBP) 24th International Research Symposium
INSPIRE trial in 22q achieved statistically significant and clinically meaningful improvements from baseline in multiple efficacy assessments, with excellent tolerability profile INSPIRE trial in 22q ...

Zynerba Pharmaceuticals to Present In-Person at the H.C. Wainwright 24th Annual Global Investment Conference
DEVON, Pa., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychi...

Zynerba Pharmaceuticals Announces Oral Presentation at The Society for the Study of Behavioural Phenotypes (SSBP) 24th International Research Symposium
DEVON, Pa., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychia...

Zynerba Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Highlights
Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with Fragile X syndrome (FXS); topline results expected second-half 2023

Zynerba Pharmaceuticals to Present In Person at the Canaccord Genuity 42nd Annual Growth Conference
DEVON, Pa., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychia...

Zynerba Pharmaceuticals Enters Into Equity Purchase Agreement for Up to $20 Million with Lincoln Park Capital
DEVON, Pa., July 21, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychia...

Zynerba Pharmaceuticals Announces Panel Presentation and Poster Presentations at the NFXF International Fragile X Conference
DEVON, Pa., July 07, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare ...

Zynerba's Cannabidiol Formulated Gel Shows Encouraging Action In Genetic Disease
Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) announced positive top-line results from the Phase 2 INSPIRE trial of Zygel (Transdermal CBD gel) on pediatric behavioral and emotional symptoms of 22q11.2 d...